Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services
FDA, U.S. Food and Drug Administration
U.S. Food & Drug Administration
 
  • A to Z Index
  • Follow FDA
  • FDA Voice Blog
Search
 
Most Popular Searches
 
  • Home
  • Food
  • Drugs
  • Medical Devices
  • Vaccines, Blood & Biologics
  • Animal & Veterinary
  • Cosmetics
  • Radiation-Emitting Products
  • Tobacco Products
 

Import Alert 66-11

  • Print
  • Share
  • E-mail
  • FDA Home
  • Import Program
  • Import Alerts
  • Imports Alerts by Number
  • Import Alert
-

(Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public).

Import Alert # 66-11
Published Date: 12/07/2012
Type: DWPE
Import Alert Name:
"Tatex Tattoo Remover"

Reason for Alert:
Three complaints of injury have implicated this drug as the source of acute inflammation, cellulitis and secondary infection of the skin. All of the complaints indicated that the tattoo remover was received through the mail from the Atlanta Co., Pickering, Ontario, Canada.

The product was received in small plastic vials labeled in part, "Tatex Tattoo Remover*** 2 1/2 cc accompanied by labeling entitled, "Instructions for use of the Tatex Tattoo Remover."

Although there has been no recent detention activity of the Tatex brand tattoo remover, the alert remains in effect because of the possibility of entry which may be attempted for similar products from other foreign manufacturers.

Guidance:
Districts may detain without physical examination products which claim to be tattoo removers.

Product Description:
Tattoo Removers

Charge:
"The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved new drug application [Unapproved New Drug, Section 505(a)]."

OASIS charge code - UNAPPROVED

Countries

MULTIPLE COUNTRIES (PODS ONLY)
(66 V - - 99) Miscellaneous Patent Medicines, Etc.
-
-

Links on this page:

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.


  • Accessibility
  • Contact FDA
  • Careers
  • FDA Basics
  • FOIA
  • No Fear Act
  • Site Map
  • Transparency
  • Website Policies
FDA
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA
  • USA.gov
  • E-mail
  • RSS
  • Twitter
  • Facebook
  • YouTube
  • Flickr
  • For Government
  • For Press
  • Combination Products
  • Advisory Committees
  • Science & Research
  • Regulatory Information
  • Safety
  • Emergency Preparedness
  • International Programs
  • News & Events
  • Training and Continuing Education
  • Inspections/Compliance
  • State & Local Officials
  • Consumers
  • Industry
  • Health Professionals
U.S. Department of Health & Human Services
 

Links on this page: